Xeris Biopharma Holdings, Inc.
XERS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $728,389 | $836,928 | $505,425 |
| - Cash | $91,598 | $59,285 | $58,440 | $71,621 |
| + Debt | $31,991 | $257,223 | $268,751 | $271,447 |
| Enterprise Value | – | $926,327 | $1,047,239 | $705,251 |
| Revenue | $74,380 | $71,539 | $60,119 | $60,099 |
| % Growth | 4% | 19% | 0% | – |
| Gross Profit | $63,384 | $56,930 | $51,391 | $50,621 |
| % Margin | 85.2% | 79.6% | 85.5% | 84.2% |
| EBITDA | $11,078 | $8,594 | $1,228 | $5,723 |
| % Margin | 14.9% | 12% | 2% | 9.5% |
| Net Income | $621 | -$1,928 | -$9,220 | -$5,113 |
| % Margin | 0.8% | -2.7% | -15.3% | -8.5% |
| EPS Diluted | 0 | -0.012 | -0.061 | -0.034 |
| % Growth | 100% | 80% | -76.4% | – |
| Operating Cash Flow | $18,432 | $182 | -$10,031 | $1,975 |
| Capital Expenditures | -$363 | $13 | -$13 | -$220 |
| Free Cash Flow | $18,069 | $10,044 | -$10,044 | $1,755 |